SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
OncoCyte Corporation (OCX) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+150%).
- 分析师共识目标价 $8.00 (+150% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 45/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
25/100
Debt-to-Equity & liquidity
→ Health
估值概览 — OCX
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率24.05
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.65
每股账面价值$0.00
每股营收$0.13
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$8.00 (+150%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$-8.42 |
$0.00 |
$-11.17M |
- |
| 2017 |
$-12.83 |
$0.00 |
$-19.38M |
- |
| 2018 |
$-8.32 |
$0.00 |
$-15.75M |
- |
| 2019 |
$-8.71 |
$0.00 |
$-22.33M |
- |
| 2020 |
$-9.14 |
$1.22M |
$-29.93M |
-2461.5% |
| 2021 |
$-14.42 |
$7.73M |
$-64.1M |
-829.5% |
| 2022 |
$-13.26 |
$958K |
$-73.44M |
-7666% |
| 2023 |
$-3.75 |
$1.5M |
$-27.78M |
-1848.4% |
| 2024 |
$-4.66 |
$1.88M |
$-60.66M |
-3225% |
| 2025 |
$-1.65 |
$4.06M |
$-50.22M |
-1238.5% |
